EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

Liliana Antunes iD, Madelyn Rojas-Castro iD, Marcos Lozano, Iván Martínez-Baz, Isabel Leroux-Roels, Maria-Louise Borg, Beatrix Oroszi iD, Margaret Fitzgerald, Ralf Dürrwald iD, Ligita Jancoriene, Ausenda Machado, Goranka Petrović und 20 weitere

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70081 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Liliana Antunes und 31 weiteren Autor:innen. Beteiligte Einrichtung: Epiconcept, Paris, France. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, SARS-CoV-2, Vaccine Efficacy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Centre for Disease Prevention and Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation during the BA.2.86/JN.1 lineage‐predominant period using a multicentre test‐negative case–control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days and 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID‐19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post‐vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationSARS-CoV-2Vaccine EfficacyCOVID-19 VaccinesHumansAgedEuropeMaleFemaleCase-Control StudiesAged, 80 and over

Stichwörter der Autor:innen

case–control studyelderlysevere acute respiratory infections (SARI)test‐negative designvaccine effectiveness

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Epiconcept, Paris, France.
  • National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.
  • Department of Infection Control, Ghent University Hospital, Ghent, Belgium.
  • Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: Liliana Antunes, Madelyn Rojas-Castro, Beatrix Oroszi, Ralf Dürrwald, Jesús Castilla, Angela M C Rose

Förderung

  • European Centre for Disease Prevention and Control

Zitieren

APA

Antunes, L., Rojas-Castro, M., Lozano, M., Martínez-Baz, I., Leroux-Roels, I., Borg, M. L., Oroszi, B., Fitzgerald, M., Dürrwald, R., Jancoriene, L., Machado, A., Petrović, G., Lazar, M., Součková, L., Bacci, S., Howard, J., Verdasca, N., Basile, L., Castilla, J., …, & VEBIS SARI VE network team (2025). Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70081

Vancouver

Antunes L, Rojas-Castro M, Lozano M, Martínez-Baz I, Leroux-Roels I, Borg ML, et al. Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70081

BibTeX
@article{Antunes2025,
  author = {Antunes, Liliana and Rojas-Castro, Madelyn and Lozano, Marcos and Martínez-Baz, Iván and Leroux-Roels, Isabel and Borg, Maria-Louise and Oroszi, Beatrix and Fitzgerald, Margaret and Dürrwald, Ralf and Jancoriene, Ligita and Machado, Ausenda and Petrović, Goranka and Lazar, Mihaela and Součková, Lenka and Bacci, Sabrina and Howard, Jennifer and Verdasca, Nuno and Basile, Luca and Castilla, Jesús and Ternest, Silke and Džiugytė, Aušra and Túri, Gergő and Duffy, Roisin and Hackmann, Carolin and Kuliese, Monika and Gomez, Verónica and Makarić, Zvjezdana Lovrić and Marin, Alexandru and Husa, Petr and Nicolay, Nathalie and Rose, Angela M C and VEBIS SARI VE network team, VEBIS SARI VE network team},
  title = {Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70081}
}
Kostenlos starten →